Article
Semi‑random mutagenesis profile of BCR‑ABL during imatinib resistance acquirement in K562 cells.
Molecular medicine reports - 1 Dec 2017
Dong Yan, Gao Xiaotong, Zhao Yingxin, Wei Mengying, Xu Lingmin, Yang Guodong, Liu Li
Abstract excerpt
Although imatinib is effective in chronic myeloid leukemia treatment, imatinib resistance due to the T315I mutation and/or other mutations is a challenge to be overcome. However, how DNA mutation occurs, particularly the T315I mutation, remains unclear. In the current study, the mutagenesis of BCR‑ABL was analyzed via focusing on the process of drug resistance, rather than the final results. Clone sequencing of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.